scPharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals or view top-rated stocks.

Wall Street analysts have given scPharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but scPharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for scPharmaceuticals.

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its earnings results on Monday, November, 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.05.
View scPharmaceuticals' earnings history.

scPharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SCPH shares have decreased by 6.2% and is now trading at $7.29.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued 12 month price targets for scPharmaceuticals' shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate scPharmaceuticals' stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 69.2% from the stock's current price.
View analysts' price targets for scPharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to scPharmaceuticals include VBI Vaccines (VBIV), Dyne Therapeutics (DYN), Chinook Therapeutics (KDNY), Merus (MRUS), Provention Bio (PRVB), Intercept Pharmaceuticals (ICPT), Xenon Pharmaceuticals (XENE), Gossamer Bio (GOSS), Calliditas Therapeutics AB (publ) (CALT), Odonate Therapeutics (ODT), Emisphere Technologies (EMIS), OrganiGram (OGI), Albireo Pharma (ALBO), Akouos (AKUS) and Rigel Pharmaceuticals (RIGL).
View all of SCPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

(SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

scPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (5.37%), Alyeska Investment Group L.P. (1.30%), Alyeska Investment Group L.P. (1.30%), BlackRock Inc. (1.18%), Renaissance Technologies LLC (0.90%) and Worth Venture Partners LLC (0.60%). Company insiders that own scPharmaceuticals stock include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp and Ra Capital Management, LP.
View institutional ownership trends for scPharmaceuticals.

SCPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ikarian Capital LLC, Worth Venture Partners LLC, Northern Trust Corp, Alyeska Investment Group L.P., and Alyeska Investment Group L.P..
View insider buying and selling activity for scPharmaceuticals or view top insider-selling stocks.

SCPH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Zacks Investment Management, Virtu Financial LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., Wells Fargo & Company MN, Dimensional Fund Advisors LP, and Dimensional Fund Advisors LP. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp, and Ra Capital Management, LP.
View insider buying and selling activity for scPharmaceuticals or or view top insider-buying stocks.

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SCPH stock can currently be purchased for approximately $7.29.

scPharmaceuticals has a market capitalization of $199.17 million. The company earns $-33,000,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

scPharmaceuticals employs 26 workers across the globe.

The official website for scPharmaceuticals is www.scpharma.com.

scPharmaceuticals is headquartered at 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830.

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]